Emcure Pharmaceuticals is acquiring the pharmaceutical portfolio of UK-based Manx Healthcare and its subsidiaries, Manx Pharma and Manx Generics, for £ 19.7 million (Rs 218 crore). Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset Purchase Agreement (APA) with Manx Healthcare and its subsidiaries. As part of this agreement, Tillomed will acquire the Manx product portfolio, along with intellectual properties, dossiers, marketing authorisations, and relevant inventory. The transaction will involve an upfront payment of £ 6.2 million, with the remainder to be paid as milestone payments over the next 18 months. Manx is a family-owned, independent pharmaceutical company specialising in affordable healthcare, particularly in generics and over-the-counter (OTC) products for pain management, dental care, gut health, and infection. Tillomed Laboratories, headquartered in Luton, UK, also has subsidiaries in Italy, Germany, and Spain. The company focuses on developing, licensing, and marketing generic medicines and operates across multiple European markets with a portfolio of over 100 products. This portfolio covers various therapeutic areas, including oncology, analgesia, cardiovascular health, women’s health, anti-infectives, anti-epileptics, gastrointestinal issues, genito-urinary health, immunosuppressants, mental health, and osteoporosis. Ajit Srimal, CEO of Tillomed, stated that the acquisition of the Manx portfolio of accessible healthcare solutions will diversify their offerings and strengthen their market presence.
Emcure’s subsidiary and dermatology company, Emcutix Biopharmaceuticals, has also entered into an exclusive licensing agreement with WiQo, an Italian derma-cosmetic and medical devices company, for non-invasive skincare treatment. Emcutix has the exclusive rights to import, promote, distribute, and sell PRX-PLUS, WiQo’s flagship needle-free skin booster, in the Indian market. PRX-PLUS is a droplet-based skincare solution that promotes immediate skin lifting without the use of injections, recovery time, or discomfort. The Indian dermatology market size is estimated to be around $ 1.8 billion, with a potential growth rate of 11-12%.